VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference
20 sept. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at...
VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference
08 sept. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at...
VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases
12 août 2021 07h30 HE
|
VYNE Therapeutics Inc.
Company announced license agreement with In4Derm Limited for BETi platform earlier this morning Company has initiated a process to explore a sale or license of its topical minocycline franchise ...
VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited
12 août 2021 07h00 HE
|
VYNE Therapeutics Inc.
VYNE will have exclusive access to a library of new chemical entities VYNE will prioritize initial development efforts on rare skin diseases and major immunology and inflammatory conditions with high...
VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone
02 août 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its products AMZEEQ® (minocycline) topical foam, 4%, and...
VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021
27 juil. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the second quarter...
VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne
19 juil. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the initiation of an investigator initiated trial (“IIT” or...
VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digital Event
29 juin 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that Dr. Iain Stuart, Chief Scientific Officer, will participate...
VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
06 mai 2021 07h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the first quarter ended March 31, 2021 and...
VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021
28 avr. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the first quarter...